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Controversies in Psychiatry and DSm-5: The Relevance 
for Social Work (Occasional Essay)
Jill littrell & Jeffrey r. lacasse
this essay addresses recent controversies surrounding the forthcoming fifth edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5—the first major revision of the DSM since 1994), as well as questions regarding the safety 
and efficacy of psychotropic medications discussed in the public domain. mental health professionals across a wide range 
of professions have signed a petition to the DSM-5 task Force protesting changes in the new edition, and critiques of 
psychiatric medications are increasingly disseminated in the media. these issues have particular relevance for children in 
foster care, who receive diagnoses and medication at high rates. the general public is increasingly exposed to information 
on these topics through the media; as advocates and clinicians, it is important that social work practitioners be informed 
regarding these issues.
controversial issues in psychiatry are relevant to social workers because they provide the major-ity of mental health services in the united states 
(Cohen, 2003; Mechanic, 2008). the controversy over 
revisions in the upcoming fifth edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) has 
been widely discussed in newspapers and by the Public 
broadcasting system’s NewsHour. the efficacy of anti-
depressants has been questioned on 60 Minutes, when 
lesley stahl (2012) interviewed irving Kirsch. recently, 
a petition (open letter to the DSM-5, 2011) launched by 
the society for humanistic Psychology and several other 
american Psychological association (aPa) divisions, 
was posted on the Web (http://www.ipetitions.com/peti-
tion/dsm5). this essay will begin with some background 
on what prompted the petition and why allen frances, 
co-chair of the fourth edition of the DSM (DSM-IV), has 
become a self-professed crusader. the relevance of the 
controversies in psychiatry to indigent children and chil-
dren in foster care will be reviewed here as well. Concerns 
about the problematic addition of new diagnoses and the 
narrowing of diagnoses elsewhere for the DSM-5 will be 
discussed. a brief overview of the controversy regarding 
antidepressants will be presented. finally, some thoughts 
regarding how social work can respond will be proffered.
The Petition
The petition (open letter to the DSM-5, 2011) asks the 
DSM-5 task force to reconsider its intention to loosen and 
expand the criteria for a variety of diagnoses. according to 
frances (2011c), this petition has been signed by more than 
5,000 mental health professionals and 17 different mental 
health professional organizations. frances (2011b) earlier 
had urged colleagues to sign the petition.
The petition to the committee developing the DSM-5 
follows earlier attempts by frances to prevent the ameri-
can Psychiatric association from “falling off a cliff” 
(greenberg, 2010). frances (2010), concerned about 
the proliferation of new diagnostic labels, published an 
article in the Los Angeles Times questioning whether 
“normality is an endangered species.” before this, fran-
ces (2009) published an article in Psychiatric Times urg-
ing caution in the development of criteria for various 
proposed disorders and decrying the unintended con-
sequences of the manner in which the DSM-IV criteria 
were stated, which led to the epidemic rise in the diagno-
ses for attention-deficit/hyperactivity disorder (adhd), 
autism spectrum disorders, and bipolar disorder. in an 
interview, frances explained his activism, “Kids getting 
unneeded antipsychotics that would make them gain 12 
pounds in 12 weeks hit me in the gut. it was uniquely my 
job and my duty to protect them. if not me to correct it, 
who? i was stuck without an excuse to convince myself” 
(greenberg, 2010).
The particular issue of children receiving antipsychotic 
medications is connected to the rise in the diagnosis of 
pediatric bipolar disorder. although the diagnosis of pe-
diatric bipolar is not in the revised DSM-IV (DSM-IV-R), 
no age restriction was placed on the adult diagnosis in the 
DSM-IV-R. When harvard university’s Joseph bieder-
man and colleagues began publishing articles reporting 
that children, many of whom had been previously labeled 
as conduct disorder or adhd, met criteria for bipolar 
disorder, the diagnosis of pediatric bipolar took off (lit-
trell & lyons, 2010a). Whereas it had been assumed that 
bipolar disorder never emerged until late adolescence or 
adulthood, by 2004 it was the most frequent diagnosis for 
children (blader & Carlson, 2007). a similar increase in 
bipolar spectrum diagnoses was witnessed for adults as 
well, according to Moreno et al. (2007).
as more children and adults were labeled bipolar, the 
use of atypical antipsychotics escalated. domino and 
swartz (2008) documented the rise in the use of atypi-
cal antipsychotics for both children and adults. Most re-
cently, Comer, Mojtabai, and olfson (2011) documented 
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an increase in the use of atypical antipsychotics for the 
treatment of anxiety disorders. as the addictive liability 
of tranquilizers has received attention, an atypical anti-
psychotic, seroquel (quetiapine), is now being used for 
insomnia (sinaikin, 2010).
While Comer et al. (2011) documented the rise in the 
use of atypical antipsychotics, others have documented 
the deleterious impact of the atypicals. in february 2011, 
ho, andreasen, Ziebell, Pierson, and Magnotta (2011) 
published their findings of brain volume reduction given 
the use of antipsychotic medications (both older neuro-
leptics and the new atypicals). While the ho et al. study 
did not use random assignment to conditions, and thus 
causality could not be inferred from their data, the re-
searchers cited animal work with the same findings, 
where random assignment was observed. after 27 months 
of dosages in the therapeutic range for people, there was 
an 11.8–15.2% reduction in the parietal lobe and a reduc-
tion in total weight of brain volume (Konopaske et al., 
2007, 2008). brain tissue volume decrement is only the 
latest recognition of the devastating impact of the atypi-
cal antipsychotics. atypicals are associated with weight 
gain that does not plateau, high levels of blood lipids, and 
increased risk of diabetes (goodwin & Jamison, 2007, 
p. 846), as well as osteoporosis (Kawai & rosen, 2010). al-
though the atypicals were initially believed to be free of 
movement disorder risks, the Clinical antipsychotic tri-
als of intervention effectiveness (Catie) study, a large 
government-funded study, revealed that the atypicals, 
like older neuroleptics, can cause movement disorder 
(Casey, 2006). additionally, the food and drug adminis-
tration (fda) has issued a warning regarding seroquel’s 
capacity to induce cardiac arrhythmias and sudden death 
(Wilson, 2011). 
Relevance to the Child Welfare System 
Children covered by Medicare and Medicaid are more 
likely to receive prescriptions for antipsychotics than 
privately insured children. high proportions of foster 
children are being medicated with antipsychotics and 
polypharmacy (dosreis, Yoon, rubin, riddle, noll, & 
rothbard, 2011; littrell & lyons, 2010b), which is costly 
(leslie & rosenheck, 2012). This is particularly trouble-
some given that few medications are fda-approved for 
children. state Medicaid programs allow for more office 
visits when there is a severe diagnosis, and supplemental 
security income (ssi) eligibility is easier to obtain with a 
severe diagnosis, both of which probably contribute to the 
increase in severe diagnoses and heavy medications (lit-
trell & lyons, 2010b). recently, push-back on these issues 
has occurred. on december 1, 2011, u.s. senator tom 
Carper held a hearing on the report of the u.s. govern-
ment accountability office (gao) investigating medica-
tion of foster children. in several states, doses were found 
that exceeded the maximum levels approved by the fda. 
across states, 0.11–1.33% of children were being treated 
concurrently with more than five medications. accord-
ing to the gao panel, “our experts also said that no evi-
dence supports the use of five or more psychotropic drugs 
in adults or children, and only limited evidence supports 
the use of even two drugs concomitantly in children” 
(gao testimony, 2011, p. 14).
Concerns regarding prepsychosis. in addition to con-
cerns about the rise in atypical antipsychotic medication 
use for children, frances (2011a) also expressed concern 
about the inclusion of a prepsychosis diagnosis in the im-
pending DSM-5. frances reported that attempts to iden-
tify those individuals who would later become psychotic 
have yielded high levels of false positives (see Thompson, 
nelson, & Yung, 2011). antipsychotics have failed to 
prevent the emergence of psychosis in high-risk groups 
(Marshall & rathbone, 2011; although the salubrious 
omega-3 fatty acids have demonstrated efficacy in pre-
venting the emergence of psychosis in those at high risk—
see amminger et al., 2010). frances fears a new diagnosis 
of prepsychosis could result in many more individuals 
being stigmatized and placed on ineffective medications 
with severe adverse effects. social worker researchers 
should endeavor to identify social factors that prevent the 
emergence of psychosis in those who are at risk so that 
prevention strategies can be developed.
Limiting diagnoses without drug treatments. ironi-
cally, the DSM-5 Committee on autism spectrum disor-
ders has suggested more stringent criteria. dr. fred Volk-
mar, director of the Child study Center at the Yale school 
of Medicine, forecasted that the new criteria would dis-
qualify many of the individuals who are currently being 
treated. Consumer advocates have protested the tighten-
ing of criteria for autism spectrum disorders, fearing the 
loss of insurance coverage of nonpharmaceutical treat-
ments (Carey, 2012). since social workers provide services 
to the developmentally disabled, this change could limit 
the ability of social workers to serve their clients.
Controversy about the efficacy of antidepressants. 
The questionable use of antipsychotics is only one of the 
latest controversies in psychiatry. speaking more broadly, 
Thomas insel, current director of the national institute 
of Mental health (niMh), reflected, “The unfortunate 
reality is that current medications help too few people get 
better and very few people to get well” (2009, p. 704). in 
Anatomy of an Epidemic, Whitaker (2010) examined each 
category of psychotropic medication in turn. he con-
trasted current outcomes of psychiatric disorders with 
outcomes for these same disorders prior to the advent of 
drugs. surprisingly, not only are current outcomes not 
any better than those prior to drugs, but for major depres-
sion and for bipolar disorder, current treatment seems to 
contribute to chronicity. Whitaker’s book was reviewed 
in New York Review of Books in the summer of 2011 by 
Marcia angell, the former editor of The New England 
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Journal of Medicine. angell pointed out the lack of data 
on long-term outcomes with psychiatric medications; 
placebo-controlled trials, often sponsored by industry, 
evaluate outcomes after only 8 weeks. Moreover, there are 
no definitive tests for any of the diagnoses in the DSM. 
angell did not disagree with Whitaker’s conclusions (an-
gell, 2011a, 2011b, 2011c). 
an exchange between angell and several psychiatrists 
(i.e., oldham, friedman, nierenberg, and Carlat) later 
was published in the New York Review of Books (2011c). 
in response to angell in the exchange, oldham argued 
that depression is undertreated and that psychiatry, as a 
whole, has never argued that “chemical imbalances are 
causes of mental disorders or the symptoms of them” 
(angell, 2011c, p. 82). friedman and nierenberg, in re-
sponse to angell, argued that physicians in other areas 
of medicine treat before they understand the conditions 
they are treating. also, in response to angell, Carlat cited 
turner and rosenthal’s (2008) defense of antidepressants, 
who wrote, “When considering the potential benefits of 
treatment with antidepressants, be circumspect but not 
dismissive” (p. 51).
The Larger Context
The subtext of the current controversies refers to cor-
ruption in the process of the writing of the DSM-5. The 
obvious “elephant in the room” behind the rise in psy-
chiatric diagnoses is the unhealthy relationship between 
academic psychiatry and the pharmaceutical industry. 
u.s. senator Charles grassley’s finance Committee in-
vestigated the degree to which prominent psychiatrists 
who set standards for practice are paid by industry, re-
vealing that several had failed to disclose the extent of 
their financial ties to drug companies (harris & Carey, 
2008). others have decried the influence of pharmaceu-
tical houses in medicine (bremner, 2011; elliot, 2010; 
sinaikin, 2010). This potential for influence extends to 
DSM-5 task force members, many of whom have finan-
cial ties to the pharmaceutical industry (Cosgrove & 
Krimsky, 2012). 
angell (2005) has published extensively on the broader 
issue of the pharmaceutical industry and purveyors of de-
vices influencing students in medical school with biased 
information. Most of the clinical trials in this country are 
funded by industry, and only positive findings are pub-
lished (turner, Matthews, linardatos, tell, & rosenthal, 
2008). given the rampant ghostwriting by industry in 
medical journals (lacasse & leo, 2010), industry-funded 
studies are sometimes best regarded primarily as market-
ing efforts rather than truth-seeking endeavors. how is 
the reader of journal articles to know when these influ-
ences are or are not present? The ramifications of this 
commercial influence on the interrelated practice of di-
agnosis and treatment by social workers are difficult to 
quantify, but certainly our profession must wrestle with 
these issues.
Action Strategies for Social Work Professionals
so how should social workers respond to these develop-
ments? The aPa has not taken a position on the online 
petition to the DSM-5 task force, although a special 
e-mail was sent to members to alert them to an article 
by rebecca Clay in the february 2012 issue of Monitor. 
Clay (2012) pointed out that most psychologists use the 
World health organization’s International Classification 
of Diseases rather than the DSM. indeed, frances (2011c) 
has suggested that mental health professionals can defect 
from using the DSM in rendering diagnoses if efforts to-
ward reform are unheeded. The national association of 
social Workers (nasW) announced the petition on its 
website but has not taken an official position. given the 
social justice orientation of our profession and our histo-
ry of critical engagement with the issue of diagnosis (e.g., 
Kutchins & Kirk, 1992; saleebey, 2001), social workers 
should read and consider signing the petition. on a macro 
level, nasW should consider entering this debate, partic-
ularly regarding the diagnosis of foster children and other 
vulnerable populations. Practicing social workers should 
familiarize themselves with the many controversies re-
lated to DSM-5 (only a few of which are addressed here), 
so that they can apply critical thinking to the question of 
diagnoses relevant to their practice context. in particular, 
practitioners should consider whether certain diagnostic 
labels drive the prescription of psychiatric medications to 
their clients, and whether other explanations or labels for 
behavior might instead facilitate the use of effective psy-
chosocial interventions for client problems (e.g., should 
major depression be diagnosed and antidepressants used 
in the wake of a major loss? see horowitz & Wakefield, 
2007). While DSM clearly serves a valid bureaucratic pur-
pose as a vehicle for reimbursement, these controversies 
illustrate the debatable science underlying many of the 
DSM categories. social work researchers should be aware 
that niMh now recognizes the problems with DSM and 
that the 21st-century research agenda for studying mental 
disorders will change substantially to move beyond such 
DSM categories (insel et al., 2010).
The closely related issue of medication is also important 
for social work to address, as social workers are involved 
in psychoeducation and related roles (bentley, Walsh, & 
farmer, 2005). serving in this role requires considerable 
preparation, and social work educators should consider 
this reality when developing curricula; course content on 
psychiatric drugs should be offered to all clinical students. 
in clinical practice, social workers should present full 
disclosure regarding any medication discussed. This re-
quires that practicing social workers be familiar with the 
efficacy of various medications, including the proportion 
of people who respond to drugs as compared to general-
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ized helping or psychotherapy, as well as the probability 
of recovering without drugs. to meet our ethical man-
date to our clients, this requires that social workers think 
critically about the source of knowledge about psychiatric 
drugs and realize the limitations of research produced by 
the pharmaceutical industry (gomory, Wong, Cohen, & 
lacasse, 2011). social workers should provide informa-
tion about withdrawal phenomena and the short- and 
long-term adverse effects of medications. Mental health 
practitioners should never instruct a client to stop tak-
ing a medication prescribed by a physician. social work-
ers can, however, provide documentation of the degree 
of efficacy of medications and their adverse effects. Then 
the client can make an informed decision when talking 
with a physician about current medications or have an in-
formed basis for declining a referral for initiating medi-
cations (see littrell & ashford, 1995, on legal issues). so-
cial workers should also be familiar with evidence-based 
psychosocial alternatives to medication; for instance, use 
of behavioral analysis and Vygotsky’s methods (bodrova 
& leong, 1996) for helping foster children develop self-
control. on a policy level, they should become informed 
about the issues regarding medicating foster children and 
advocate for stringent guidelines at the state level. Psy-
chrights (http://www.psychrights.org/index.htm) website 
describes national protection efforts for children in foster 
care and specifics in what social workers can do. finally, 
social work researchers should more aggressively probe 
the influence of the pharmaceutical industry on practice 
(see stoesz, 2012) and advocate for more integrity in the 
process of conducting studies and disseminating infor-
mation. in an era of evidence-based practice, the verac-
ity and objectivity of peer-reviewed research is a deeply 
important issue (gambrill, 2012).
With regard to further advocacy, the initial phase 
is providing documentation of a problem. hopefully, 
this essay will alert the social work community to what 
is problematic about the manner in which we currently 
conceptualize and respond to human suffering. our hope 
is that these issues will be further debated and discussed.
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